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Abstract  
Background 
The epidermal growth factor receptor (EGFR) is frequently overexpressed in many 
cancers, including non-small cell lung cancer (NSCLC). In silcio modeling is 
considered to be an increasingly promising tool to add useful insights into the 
dynamics of the EGFR signal transduction pathway. However, most of the previous 
modeling work focused on the molecular or the cellular level only, neglecting the 
crucial feedback between these scales as well as the interaction with the 
heterogeneous biochemical microenvironment. 
Results 
We developed a multiscale model for investigating expansion dynamics of NSCLC 
within a two-dimensional in silico microenvironment. At the molecular level, a 
specific EGFR-ERK intracellular signal transduction pathway was implemented. 
Dynamical alterations of these molecules were used to trigger phenotypic changes at 
the cellular level. Examining the relationship between extrinsic ligand concentrations, 
intrinsic molecular profiles and microscopic patterns, the results confirmed that 
increasing the amount of available growth factor leads to a spatially more aggressive 
cancer system. Moreover, for the cell closest to nutrient abundance, a phase-transition 
emerges where a minimal increase in extrinsic ligand abolishes the proliferative 
phenotype altogether. 
Conclusions 
Our in silico results indicate that, in NSCLC, in the presence of a strong extrinsic 
chemotactic stimulus, and depending on the cell’s location, downstream EGFR-ERK 
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signaling may be processed more efficiently, thereby yielding a migration-dominant 
cell phenotype and overall, an accelerated spatio-temporal expansion rate.  
 
Background  
Non-small cell lung cancer (NSCLC) remains at the top of the list of cancer-related 
deaths in the United States [1]. The epidermal growth factor receptor (EGFR) is 
frequently overexpressed in NSCLC [2, 3]. Binding of epidermal growth factor (EGF) 
or transforming growth factor alpha (TGFα) to the extracellular domain of EGFR 
produces a number of downstream effects that affect phenotypic cell behavior 
including proliferation, invasion, metastasis, and inhibition of apoptosis [4]. In 
particular, increasing the expression of these growth factors leads to EGFR 
hyperactivity [5, 6], and thus increases tumor cell motility and invasiveness, and 
finally enhances lung metastasis [7, 8]. Since approximately 90% of all cancer deaths 
originate from the spread of primary tumor cells into the surrounding tissue [9], 
quantitative measurements of the relationship between the level of the growth factors 
and the resulting tumor expansion is crucial - all the more so, since EGFR has 
emerged as an attractive therapeutic target for patients with advanced NSCLC [10]. 
 
A number of EGFR-related intracellular signal transduction pathways have been 
studied [11-16], including NSCLC [17], and corresponding computational models at 
the molecular-level have been developed. These quantitative works mainly focused on 
signal-response relationships between the binding of EGF to EGFR and the activation 
of downstream proteins in the signaling cascade. With these in silico approaches, 
experimentally testable hypotheses can be made on signaling events controlling 
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divergent cellular responses such as cell proliferation, differentiation, or apoptosis [18, 
19]. However, most signaling works did not yet consider the cellular level (see [20, 
21] for a review), and, conversely, only a few recent EGF/EGFR-mediated cellular-
level models have started to incorporate a simple molecular level in studying e.g., cell 
migration in breast cancer [22], cell proliferation [23], and autocrine receptor-ligand 
dynamics [24, 25]. We argue that a more detailed understanding of a complex cancer 
system requires integrating both molecular- and cellular-level works to properly 
examine multicellular dynamics. To our knowledge, to date, no multiscale model of 
NSCLC has been developed or published.   
 
Our group has been developing multiscale models to investigate highly malignant 
brain tumors as complex dynamic and self-organizing biosystems. Since this NSCLC 
model builds on these works, we will briefly review some milestones. First, an agent-
based model for studying the spatio-temporal expansion of virtual glioma cells in a 
two-dimensional (2D) environment was built and the relationship between rapid 
growth and extensive tissue infiltration was investigated [26, 27]. This ‘micro-macro’ 
framework was then extended ‘top-down’ by incorporating an EGFR molecular 
interaction network [28] so that molecular dynamics at the protein level could be 
related to multi-cellular tumor growth patterns [29]. Most recently, an explicit cell 
cycle description was implemented to study in more detail tumor growth dynamics in 
a three-dimensional (3D) context of a virtual brain tumor [30]. These previous works 
have provided a computational paradigm in which biological processes have been 
successfully simulated from the molecular scale up to the cellular level and beyond. 
This progress led us to test the platform’s applicability to and flexibility for other 
cancer types as well.   
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In this paper, we have therefore extended these previous modeling works to the case 
of NSCLC. Necessary modifications include at the molecular level the 
implementation of a NSCLC-specific EGFR-ERK signal transduction pathway. A 
novel, data-driven switch that is operated by two key molecules, i.e. phospholipase Cγ 
(PLCγ) and extracellular signal-regulated kinase (ERK), processes the phenotypic 
decision at the cellular level.  The aim of this in silico work is to provide insights into 
the externally triggered molecular-level dynamics that govern phenotypic changes and 
thus impact multicellular patterns in NSCLC. In the following sections, we will first 
show the detailed design of the model before we present and then discuss the 
simulation results.  
 
Model 
Molecular Signaling Pathway 
The kinetic model of the implemented NSCLC-specific molecular signaling pathway, 
which consists of 20 molecules, is shown in Fig. 1. These proteins, including both 
receptor (EGFR) and non-receptor kinases (e.g., PLCγ and protein kinase C (PKC) 
[31, 32], Raf, mitogen-activated protein kinase kinase (MEK), and ERK [33-35]), 
have been experimentally or clinically proven to play an important role in NSCLC 
tumorigenesis. Although in reality these molecules fulfil their functions by interacting 
with a multitude of other molecular species from many distinct pathways [36, 37], we 
choose to start with these proteins not only because of their significance in the case of 
NSCLC but also since most of their kinetic parameters can be found in the literature. 
Also, it is reasonable to reduce the number of involved molecules as a starting point 
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for modeling [38]. Amongst these proteins, both PLCγ and ERK are of particular 
interest for determining the cell’s phenotypic changes as we will detail below. 
 
Figure 1 
 
Kinetic equations are written in terms of concentrations and the reaction rates are 
functions of concentrations. The association and dissociation steps are characterized 
by first-order and second-order rate constants, respectively. We note that, although in 
reality chemical reactions of second or higher order are two-step processes, they are 
usually treated as a one-step process in mathematical modeling [39]. Our model is 
based on a total of 20 ordinary differential equations (ODEs) and uses exactly the 
same modeling techniques as other pathway analysis studies (see [11, 12] for detailed 
definitions). For simplicity, the ODEs for different molecules were calculated by Eq. 
(1):  
 
∑∑ −= nConsumptioProduction
i )( vv
dt
Xd
       (1) 
 
where Xi represents one of these 20 molecular pathway components. In Eq. (1), the 
change in concentration of molecule Xi is the result of the reaction rates producing Xi 
minus the reaction rates consuming it. Each biochemical reaction is then characterized 
by vi (see Fig. 1) with forward and reverse rate constants. Tables 1 and 2 summarize 
the kinetic parameters and the ODEs used for the model. 
 
Table 1 
Table 2 
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Micro-Environment 
The 2D virtual micro-environment is made up of a discrete lattice consisting of a grid 
with 200 x 200 points (Fig. 2). We use p(i,j) to express each point in the lattice, where 
i and j indicate the integer location in Euclidean terms. One single, distant nutrient 
source (simulating a cross-sectional blood vessel) is located at p(150, 150). To start 
with, a number of M x N cells (in other words, an M-by-N matrix) are initialized in 
the center of the lattice (and this number can be set to meet different simulation 
purposes). Each grid point can be occupied with one cell only or remain empty at a 
time.  
 
Figure 2 
 
Three external chemical cues are employed in the model: EGF, glucose and oxygen 
tension. As we have done in previous studies [29, 30], the nutrient source carries the 
highest value of these three diffusive cues, which implicates that it is the most 
attractive location for the chemotactically acting tumor cells. Then, by means of 
normal distribution, each grid point of the lattice is assigned a concentration profile of 
these three cues. The levels of these distributions are weighted by the distance, dij, of 
a given grid point from the nutrient source. The distributions of these three cues are 
described by the following equations:  
 
)/2exp( 22 tijmij dTEGF σ−⋅=                      (2) 
)/2exp()( 22 gijamaij dGGGoseGluc σ−⋅−+=                                       (3) 
)/2exp()( 22 oijamaij dOOOOxygen σ−⋅−+=                             (4) 
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Moreover, the three chemotactic cues continue to diffuse over the lattice throughout 
the entire process of a simulation with a fixed rate, using the following equation:  
 
,
2 ij
M
ij
MD
t
M
∇⋅=
∂
∂
  t = 1,2,3,… .       (5) 
 
where M represents one of the three external cues, and t represents a time step. The 
coefficients in Eqs. (2-5) are listed in Table 3 (see also [30] for more details). It is 
evident then that the closer a given location is to the nutrient source, the higher the 
levels of the three cues will be at this grid point. Glucose will be continuously taken 
up by cells to support their metabolism. Only the nutrient source, p(150, 150), is 
replenished at each time step while all other grid points are not. In addition, cells take 
up both their own EGF and that secreted by adjoining cells in our model, because 
cancer cells act in both autocrine and paracrine manner in consuming EGF [40, 41]. 
(We note that for simplicity we treat both EGFR ligands, EGF and TGFα as being 
identical). 
 
Table 3 
 
Each cell encompasses a self-maintained molecular interaction network (shown in Fig. 
1) and the simulation system records the molecular composite profile at every time 
step to determine the cell’s phenotype for the next step. In between time steps, the 
chemical environment is being updated, including EGF and glucose concentration as 
well as oxygen tension (according to Eq. (5)). When the first cell reaches the nutrient 
source the simulation run is terminated. 
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Cellular Phenotype Decision 
Four tumor cell phenotypes are considered in the model: proliferation, migration, 
quiescence and death. Cell death is triggered when the on site glucose concentration 
drops below 8 mM [42]. A cell turns quiescent when the on site glucose concentration 
is between 8 mM and 16 mM, when it does not meet conditions for migration or 
proliferation (see below), or when it cannot find an empty location to migrate or 
proliferate into.  
 
The most important two phenotypic traits for spatio-temporal expansion, i.e. 
migration and proliferation, are decided by evaluating the dynamics of the following 
critical intracellular molecules. (1) PLCγ is known to be involved in directing cell 
movement in response to EGF [43-45]; PLCγ dynamics are accelerated during 
migration in cancer cells [46]. Therefore, in our model, the rate of change of PLCγ 
(ROCPLC) decides if a cell proceeds to migration or not. That is, if ROCPLC exceeds a 
certain set threshold, TPLC, the cell has the potential to migrate. (2) Similarly, the rate 
of change of ERK (ROCERK) decides if a cell proceeds with proliferation. ERK has 
been found experimentally to have a strong influence on cell proliferation [33, 47, 48], 
and transient activation of ERK with EGF leads to cell replication [49, 50]. If a cell 
decides to migrate or proliferate, it will search for an appropriate location to move to 
or for its offspring to reside in. Candidate locations are those grid points surrounding 
the cell. Implementing a cell surface receptor-mediated chemotactic evaluation, the 
most appropriate location is detected by using a ‘search-precision’ mechanism [27] 
according to: 
 
ijijij LT εψψ ⋅−+⋅= )1(         (6) 
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where Tij represents the perceived attractiveness of location p(i,j),  Lij represents the 
result of an evaluation function for location p(i,j) (see [27] for the definition of Lij), 
and ε~N(µ,σ2) is an error term following a normal distribution with mean µ and 
variance σ2. ψ∈[0,1] denotes the search-precision parameter that for a given run is 
held constant for all cells. Briefly, for a given cell at a certain location, when ψ = 0 the 
cell performs a pure random walk, whereas when ψ = 1 the cell always selects the 
location with the highest glucose concentration. Based on previous results [26], we set 
ψ = 0.7 because this value tends to lead to the highest average velocity of the tumor’s 
spatial expansion.  
 
It is worth noting that even if ROCPLC or ROCERK exceed their corresponding 
thresholds, it does not necessarily have to lead to cell migration or proliferation. 
Rather, if nowhere else to go, the cell remains quiescent and continues to search for 
an empty location at the next time step. 
 
Figure 3 
 
Any cell in the process of changing its phenotype will fall into one of these four 
categories: (i) ROCPLC < TPLC and ROCERK < TERK; (ii) ROCPLC > TPLC and ROCERK 
< TERK; (iii) ROCPLC < TPLC and ROCERK > TERK; and (iv) ROCPLC > TPLC and 
ROCERK > TERK. Figure 3 lists these conditions and their phenotypic consequences, 
respectively. Following the first three cell decisions is straightforward; first, if a cell 
experiences condition (i) no phenotypic change results as both ROCPLC and ROCERK 
remain below their corresponding thresholds; however, if a cell faces condition (ii) 
the cell migrates because of ROCPLC exceeding its threshold while in the presence of 
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(iii) the cell proliferates due to ROCERK exceeding its threshold. However, for (iv), 
and in the absence of any specific experimental data, i.e. for the case that both 
ROCPLC and ROCERK exceed their corresponding thresholds, we explored two 
hypotheses: ‘rule A’ yielding migration advantage (i.e., the cell decides to migrate) 
whereas ‘rule B’ resulting in a proliferation advantage (i.e., the cell decides to 
proliferate). For simplicity, decision rules for the first three conditions are referred to 
‘general rules’, while rules A and B are referred to ‘special rules’ hereafter. In the 
following section, we will describe the corresponding simulation results.  
 
Results  
Our algorithm was implemented in C/C++. A total of 49 seed cells were initially set 
up in the center of the lattice, and these cells were arranged in a 7 x 7 square shape 
(i.e., M = 7 and N = 7, see Fig. 2 for the configuration of the seed cells). We defined 
cell IDs from 0 to 48 (left to right, bottom to top). To investigate cell expansion 
dynamics, we monitored all cells and recorded their molecular profiles at every time 
step. We are particularly interested in the following four boundary cells: Cell No 0 
(bottom-left corner, farthest from the source), Cell No 6 (top-left corner), Cell No 42 
(bottom-right corner), and Cell No 48 (top-right corner, closest to the source). 
Through the distinct micro-environmental conditions they face, these corner cells 
exemplify the impact of location on single cell behavior, while they however still 
grasp the nature of the entire system. As described before, both rules A and B were 
tested for each different simulation condition (except the data reported in Figures 6 
and 7 which result from investigating rule A only). 
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Multi-Cellular Dynamics 
Figure 4 shows two simulation results for rules A and B, respectively. The 
simulations were conducted with a standard EGF concentration of 2.56 nM. Note that 
this concentration is derived from the literature [51, 52] and has been rescaled to fit 
our model as a benchmark starting point for further simulations. In the upper panel of 
Fig. 4(a) for rule A, tumor cells first display on site proliferation prior to exhibiting 
extensive migratory behavior towards the nutrient source. However, for rule B (lower 
panel), cells remain stationary proliferative throughout, thereby increasing the tumor 
radius yet without substantial mobility-driven spatial expansion. The run time for the 
latter case (rule B) was considerably longer than for rule A. Based on the criterion 
chosen for terminating the run, i.e. the first cell reaching the nutrient source, this 
result is somewhat expected since rule A favors migration whereas rule B promotes 
proliferation. This is further supported by analysis of the evolution of the various 
phenotypes and the change of [total] cell numbers (Fig. 4(b)). While both rules 
generate all three cell phenotypes (proliferation (dark blue), migration (red), and 
quiescence (green)), rule A (left panel) indeed appears to result in a cancer cell 
population that exhibits a larger migratory fraction than the one emerging through rule 
B (right panel) which, however, yields a larger portion of proliferative cells (light 
blue). It is thus not surprising that for rule B, the [total] cell population of the tumor 
system exceeds the one achieved through rule A by a factor of 10.  
 
Figure 4 
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Influence of Decision Rules on Phenotypic Changes 
To better understand the significance of each rule for the tumor system, we have 
investigated its influence on generating the intended phenotype. Figure 5 shows the 
weight of rule A on migration (a), and that of rule B on proliferation (b). (The results 
are taken from the two simulation runs reported in Fig. 4). In Fig. 5(a), migrations 
derive from two sources: (1) general rule, i.e. [ROCPLC > TPLC and ROCERK < TERK] 
and (2) rule A; proliferations stem from one source only, i.e. if [ROCPLC < TPLC and 
ROCERK > TERK]. Rule A plays a more dominant role in triggering migrations than the 
general rule does, yet does not contribute to increasing proliferations. Likewise, rule 
B has influence on proliferation only (Fig. 5(b)) and it contributes more to inducing 
proliferations than the corresponding general rule does too.  
 
Figure 5 
 
However, as documented in the linear least square fittings, the rate at which rule A 
causes an increase in migration exceeds by far the one by which rule B induces an 
increase in proliferation. This indicates that the influence of rule A on increasing 
migrations is more substantial than that of rule B on increasing proliferations. Being 
particularly interested in gaining insights into spatially aggressive tumors, we 
continue in the following with investigating the implications of rule A on microscopic 
and molecular level dynamics of the cancer system. 
 
Phase-Transition at Molecular Level 
To further investigate (for rule A) the relationship between EGF concentration and 
phenotypic changes we varied the extrinsic EGF concentration from the standard 
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value of 2.65 x 1.0 nM to 2.65 x 50.0 nM by an incremental increase of 0.1 nM in 
each simulation. As a result of the model’s underlying chemotactic search paradigm, 
expectedly a simulation under the condition of a higher extrinsic EGF concentration 
finished faster than that with a lower one. However, cells turn out not to exhibit 
completely homogeneous behavior. 
 
Specifically, we focus on Cell No 48, the cell closest to the nutrient source, and report 
its corresponding molecular changes in Fig. 6. One can see that as the standard EGF 
concentration increases, the number of proliferations (blue) decreases gradually up to 
a phase transition between 2.65 x 31.1 and 2.65 x 31.2 nM. That is, if the standard 
EGF concentration is less than 2.65 x 31.1 nM, proliferation still occurs in this 
particular cell, but if the ligand concentration starts to exceed 2.65 x 31.2 nM, its 
proliferative trait entirely disappears. That is, in the presence of nutrient abundance, a 
very minor increase in extrinsic EGF can apparently abolish the expression of a 
phenotype. Even more intriguing, although the subcellular concentration change 
appears to be rather similar with regards to its patterns, on a closer look, the peak 
maxima of the rate changes for PLCγ and the turning point of the rate changes for 
ERK occur at an earlier time point for increasing EGF concentrations. This finding 
suggests that in the presence of excess ligand, the here implemented intracellular 
network switches to a more efficient signal processing mode. We note that for cell IDs 
0, 6, and 42, no such phase transition emerged (data not shown) hence further 
supporting that this behavior is concentration dependent, and that geography, i.e. a 
cell’s position relative to nutrient abundance, matters. Confirming the robustness of 
our finding for Cell No 48 we note that this cell continued to experience a phase 
transition when the coordinates of the center of the initial 49 cells was set randomly 
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within a square region where p(100,100) is the lower left corner and p(110,110) is the 
upper right corner (5 runs, data not shown).  
 
Figure 6 
 
Discussion & Future Works 
While using mathematical models to investigate the behavior of signaling networks is 
hardly new, understanding a complex biosystem, such as a tumor, by focusing on the 
analysis of its molecular or cellular level separately or exclusively is insufficient, 
particularly if it excludes the interaction with the surrounding tissue. Recent analyses 
of signaling pathways in mammalian systems have revealed that highly connected 
sub-cellular networks generate signals in a context dependent manner [53]. That is, 
biological processes take place in heterogeneous and highly structured environments 
[54] and such extrinsic conditions alone can induce the transformation of cells 
independent of genetic mutations as has been shown for the case of melanoma [55]. 
Taken together, modeling of cancer systems requires the analysis and use of signaling 
pathways in a simulated cancer environment (context) across different spatial-
temporal scales.  
 
Our group has been focusing on the development of such multiscale models for 
studying highly malignant brain tumors [27, 29, 30, 56]. Here, on the basis of these 
previous works, we presented a 2D multiscale agent-based model to simulate NSCLC. 
Specifically, we monitored how, dependent on microenvironmental stimuli, molecular 
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profiles dynamically change, and how they affect a single NSCLC cell’s phenotype 
and, eventually, multicellular patterns.  
 
Proceeding top-down in our analysis, we first evaluated the multicellular readout of 
molecular ‘decision’ rules A and B (versus general rules; Fig. 3). The patterns of a 
more stationary, concentrically growing cancer system (following rule B) are quite 
different from the rapid, chemotactically-guided, spatial expansion that can be seen in 
the tumor regulated by rule A (Fig. 4(a)). Not surprisingly, the latter also operates 
with many more migratory albeit overall less [total] cells (Fig. 4(b)). Furthermore, 
examining in more detail the influence of the two distinct rules on their respective 
phenotypic yield, we found that the impact of rule A on increasing cell migration is 
more substantial than rule B’s influence on furthering proliferation (Fig. 5). This 
finding suggests that the migratory rule A can operate the cancer system through 
incrementally smaller changes (while the simulation system is more robust for rule B). 
Such sensitivity to migratory cues corresponds well with experimental data on the 
response of human breast cancer cells, which showed that a spatially successful 
expansive system reacts rather quickly to even miniscule changes in chemotactic 
directionality [57, 58].  
 
Continuing therefore with rule A, our effort was then geared to gain insights into 
tumor expansion dynamics not only with regards to extrinsic stimuli but also to cell 
geography, i.e. a cell’s location relative to the replenished nutrient source. Most 
interestingly, we found a phase transition in the cancer cell closest to the nutrient 
source (i.e. Cell No 48, while none of the other three corner cells showed similar 
behavior). Specifically, for a tumor cell at this location, i.e., facing nutrient abundance, 
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proliferation is completely abolished once the extrinsic EGF concentration exceeds a 
certain level. While this at first may seems rather unexpected, this finding however 
only confirms the experimentally sound notion that EGF stimulates the spatial 
expansion of a cancer system [5-8]. Moreover, with increasing EGF concentrations, 
the maxima of ROCPLC (Fig. 6) gradually occur earlier which seems to indicate that, 
under these conditions, the downstream signal is processed faster. Interestingly, such 
a ‘no proliferation, just migration’ behavior in the presence of chemo-attractant has 
indeed already been reported in several in vitro studies using a variety of cancer cell 
lines [59, 60] as well as in non-cancerous human cells [61]. (While admittedly, for the 
reasons stated, rule B did not receive similar attention in our analysis), we nonetheless 
argue that, on the basis of our results and the experimental reports they seem to 
correspond with, rule A and thus a migratory decision prompted by a [ROCPLC > TPLC 
and ROCERK > TERK] condition is a reasonable outcome for the signaling process 
taking place in NSCLC also in vitro and in vivo.  
 
However, moving the model closer to reality will require a multitude of adjustments, 
one of which is its ability to account for up- or down-regulation in key molecules as a 
result of tumorigenesis. As a first step, and since experimental data on over-
expression of EGFR in a variety of cancer types, including NSCLC, are ample [62-
65] we have begun to simulate the impact of an increasing number of receptors on the 
cancer system (Fig. 7; simulations conducted with an EGFR concentration of 800 nM 
(per system)). Comparing this preliminary data with those reported in Fig. 6 
(simulations conducted with an EGFR concentration of 80 nM (per system)), we find 
that an EGFR-overexpressing NSCLC tumor seems to operate with even more 
migration and does so earlier on. The result is a spatially even more aggressive cancer 
Zhihui Wang et al.: Simulating non-small cell lung cancer 
 
 - 18 - 
system, which seems to correspond well with the aforementioned experimental 
studies. And, intriguingly, while the phase transition itself is preserved, it however 
occurs already at a smaller EGF concentration, hence indicating that the increase in 
receptor density leads to an amplification of the downstream signal, which again 
corresponds well with experimental results in examining signaling activities generated 
by different EGFR family members [66]. Taken together, while preliminary, this 
finding demonstrates applicability and confirms flexibility of this multiscale platform, 
hence warrants its further expansion.  
 
Figure 7 
 
There are a number of research tracks that can and should be pursued in future works. 
First, it will be intriguing to see if, in the presence of a non-replenished nutrient 
source, the proliferative phenotype eventually can be recovered once extrinsic ligand 
concentrations fall beyond the phase-transition threshold. More generally, while most 
of the pathway’s parameters, including rate constants and initial component 
concentrations were obtained from the experimental literature, this data naturally 
originated from a variety of often stationary experimental settings and different cell 
types. It therefore represents a less desirable and reliable input than time series data 
that come from one experimental setting only. Also, some parameters had to be 
estimated, much like in other well-established pathway models [11, 12]. Taken 
together, future works will have to include not only proper experimental verification 
of the estimated parameters and evaluation of the simulation results but also, on the in 
silico side, techniques such as sensitivity analysis to help determine the effects of 
parameter uncertainties on model outcome [67] and to identify control points for 
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experiment design [68]. While a pathway model cannot be a biological representation 
in every detail [38] we plan on adding, in incremental steps, other pathways of 
relevance for NSCLC such as e.g. PI3K/PTEN/AKT [69]. Moreover, simulating a 
more heterogeneous biochemical environment and implementing both cell-cell and 
cell-matrix interactions [70] are planned steps at the cellular level that should help 
representing the cancer system of interest in more detail.  
 
Regardless, we believe that the current model already provides useful insights into 
NSCLC from a systematic view in terms of quantitatively understanding the 
relationship between extrinsic chemotactic stimuli, the underlying properties of 
signaling networks, and the cellular biological responses they trigger. Our results 
yield several experimentally testable hypotheses and thus further support the use of 
multiscale models in interdisciplinary cancer research. To our knowledge, this 
presents the first multiscale computational model of Non-Small Cell Lung Cancer and 
is thus potentially a significant first step towards realizing a fully validated in silico 
model for this devastating disease.  
 
List of abbreviations used 
EGF = epidermal growth factor; EGFR = EGF receptor; ERK = extracellular signal-
regulated kinase; MAPK = mitogen-activated protein kinase; MEK = MAPK kinase; 
NSCLC = non-small cell lung cancer; PLCγ = phospholipase Cγ; PKC = protein 
kinase C; TGFα = transforming growth factor α.  
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Figures 
Figure 1  - Kinetic model of the NSCLC-specific EGFR signaling pathway 
The arrows represent the reactions specified in Tables 1 and 2. 
Figure 2  - Two-dimensional virtual micro-environment 
Depicted are the 200 x 200 lattice (left) with the position of the nutrient source, and 
the seed cells with assignment of the corner cell IDs (0, 6, 42, and 48).  
Figure 3  - Cell phenotypic decision algorithm 
See text for more details.  
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Figure 4  - Multicellular tumor expansion dynamics 
(a) Shows the multicellular patterns that emerge through rule A (upper panel) and 
rule B (lower panel), respectively. (b) Describes the numeric evolution (y-axis) of 
each cell phenotype as well as of the [total] cell population (light blue) over time (x-
axis) for rule A (left panel) and rule B (right panel), respectively. Note: proliferative 
tumor cells are labeled in dark blue, migratory cells in red, quiescent cells in green 
and dead cells in grey. 
Figure 5  - Weight of decision rules on changing cell phenotypes 
Influence on changing cell migration (left panel) and proliferation (right panel) when 
following the corresponding rule (see Fig. 3). The dashed red line indicates rule A-
mediated migrations in (a), while the dashed blue line denotes rule B-mediated 
proliferations in (b). Fitting curves in solid black are calculated using a standard linear 
least squares method. Slopes of the fitting curves are 1.40 cells/step in (a) and 0.03 
cells/step in (b), respectively. Note: The drop of the dashed red line in the left panel of 
(a) is caused by the termination of the simulation when a cell reached the source (in 
this case, no further computation on remaining cells will be performed). 
Figure 6  - Changes at the molecular level for Cell No 48 with an increasing 
extrinsic EGF concentration (rule A) 
Four simulation runs are depicted where (from left to right) the EGF concentration 
increases from 2.65 x 1.0 to 2.65 x 31.1, 2.65 x 31.2, and finally, to 2.65 x 50.0 nM. 
(From top to bottom) plotted are the absolute change of PLCγ, rate of change of PLCγ, 
and rate of change of ERK. Note that the number of proliferations is decreasing 
gradually and finally disappears at a phase transition between the EGF concentrations 
of 2.65 x 31.1 and 2.65 x 31.2 nM. (For phenotype labeling see Fig. 4). 
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Figure 7  - Changes at the molecular level for Cell No 48 with an increasing 
extrinsic EGF concentration (rule A), at an EGFR concentration of 800 nM 
Three simulation runs are depicted where (from left to right) the EGF concentration 
increases from 2.65 x 1.0 to 2.65 x 5.9 and 2.65 x 6.0 nM. (From top to bottom) 
plotted are the absolute change of PLCγ, rate of change of PLCγ, and rate of change 
of ERK. Note that a phase transition emerges again between the EGF concentrations 
of 2.65 x 5.9 and 2.65 x 6.0 nM, hence at a lower concentration compared to the one 
depicted in Fig. 6 (EGFR concentration of 80 nM) . In the two simulations around the 
phase transition, the maximum rates of change for both PLCγ and ERK (i.e., ROCPLC 
and ROCERK at 2.65 x 5.9 and at 2.65 x  6.0 nM) are lower compared with those in 
Fig. 6 (i.e., ROCPLC and ROCERK at 2.65 x 31.1 and at 2.65 x  31.2 nM). (For 
phenotype labeling see Fig. 4). 
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Tables 
Table 1  - Kinetic equations and initial concentrations  
See Table 2 for references. 
Reactant Molecular variable Initial concentration [nM] ODE 
X1 EGF to be varied d(X1)/dt = −v1 
X2 EGFR 80 d(X2)/dt = −v1 
X3 EGF-EGFR 0 d(X3)/dt = v1 − 2v2 
X4 (EGF-EGFR)2 0 d(X4)/dt = v2 + v4 − v3 
X5 EGF-EGFR-P 0 d(X5)/dt = v3 + v7 − v4 − v5 
X6 PLCγ 10 d(X6)/dt = v8 − v5 
X7 EGF-EGFR-PLCγ 0 d(X7)/dt = v5 − v6 
X8 EGF-EGFR-PLCγ-P 0 d(X8)/dt = v6 − v7 
X9 PLCγ-P 0 d(X9)/dt = v7 − v8 − v9 − v10 
X10 PLCγ-P-I 0 d(X10)/dt = v9 
X11 PKC 10 d(X11)/dt = −v10 
X12 PKC* 0 d(X12)/dt = v10 − v11 
X13 Raf 100 d(X13)/dt = −v11 
X14 Raf* 0 d(X14)/dt = v11 −v12 −v14 
X15 MEK 120 d(X15)/dt = v13 − v12 
X16 MEK-P 0 d(X16)/dt = v12 + v15 − v13 − v14 
X17 MEK-PP 0 d(X17)/dt = v14 − v15 − v16 − v18 
X18 ERK 100 d(X18)/dt = v17 − v16 
X19 ERK-P 0 d(X19)/dt = v16 + v19 − v17 − v18 
X20 ERK-PP 0 d(X20)/dt = v18 − v19 
 
   
- PKC* and Raf * indicate the activated form of PKC and Raf, respectively. 
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Table 2  - Kinetic parameters 
Concentrations and the Michaelis-Menten constants (K4, K8, and K11–K19) are given 
in [nM]. First- and second-order rate constants are given in [s-1] and [nM-1 · s-1], 
respectively. V4, V8, and V11–V19 are expressed in [nM · s-1]. 
Reaction 
number Equation Kinetic parameter Reference 
v1 k1 · X1 · X2 − k-1 · X3 k1=0.003 k-1=0.06 [11] 
v2 k2 · X3 · X3 − k-2 · X4 k2=0.01 k-2=0.1 [11] 
v3 k3 · X4 − k-3 · X5 k3=1  k-3=0.01 [11] 
v4 V4 · X5 / (K4 + X5) V4=450 K4=50 [11] 
v5 k5 · X5 · X6 − k-5 · X7 k5=0.06  k-5=0.2 [11] 
v6 k6 · X7 − k-6 · X8 k6=1  k-6=0.05 [11] 
v7 k7 · X8 − k-7 · X5 · X9 k7=0.3 k-7=0.006 [11] 
v8 V8 · X9 / (K8 + X9) V8=1  K8=100 [11] 
v9 k9 · X9 − k-9 · X10 k9=1 k-9=0.03 [11] 
v10 k10 · X9 · X11 − k-10 · X12 k10=0.214 k-10= 5.25 Estimate 
v11 V11 · X12 · X13/ (K11 + X13) V11=4 K11=64 [39] 
v12 V12 · X14 · X15 / [K12 · (1 + X16 / K14) + X15] V12=3.5 K12=317 [14] 
v13 V13 · X16 / [K13 · (1 + X17 / K15) + X16] V13=0.058 K13=2200 [12] 
v14 V14 · X14 · X16 / [K14 · (1 + X15 / K12) + X16] V14=2.9 K14=317 [12] 
v15 V15 · X17 / [K15 · (1 + X16 / K13) + X17] V15=0.058 K15=60 [12] 
v16 V16 · X17 · X18 / [K16 · (1 + X19 / K18) + X18] V16=9.5 K16=1.46 × 105 [12] 
v17 V17 · X19 / [K17 · (1 + X20 / K19) + X19] V17=0.3  K17=160 [12] 
v18 V18 · X17 · X19 / [K18 · (1 + X18 / K16) + X19] V18=16  K18=1.46 × 105 [12] 
v19 V19 · X20 / [K19 · (1 + X19 / K17) + X20] V19=0.27 K19=60 [12] 
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Table 3  - Coefficients of distribution and diffusion of EGF, glucose and oxygen 
tension  
Values are taken from the literature [71, 72]. 
Coefficient Value Units Description 
Tm 2.56 nM Maximum concentration of EGF 
Ga 17.0 mM Normal concentration of glucose 
Gm 57.0 mM Maximum concentration of glucose 
Oa 0.0017 DC Normal concentration of oxygen 
Om 0.0025 DC Maximum concentration of oxygen 
DEGF 6.7 x 10-11 m2 · s-1 Diffusion coefficient of EGF 
DGlucose 5.18 x 10-11 m2 · s-1 Diffusion coefficient of glucose 
DOxygen 8.0 x 10-9 m2 · s-1 Diffusion coefficient of oxygen 
 
  
 
 
 
